LG Chem Anti-LILRB1 Antibody Patent US12606620B2

Tue, 21 Apr 2026 13:30:11 +0000
Intellectual Property

The USPTO granted Patent US12606620B2 to LG CHEM, LTD. on April 21, 2026, covering an anti-LILRB1 antibody with increased specificity and its uses in treating cancer. The patent includes 17 claims and covers the antibody or antigen-binding fragments thereof.